Salarius Pharmaceuticals with ticker code (SLRX) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 5 and 3.8 with a mean TP of 4.43. Now with the previous closing price of 1.87 this would imply there is a potential upside of 136.9%. The 50 day MA is 1.77 and the 200 moving average now moves to 1.08. The market cap for the company is $38m. Find out more information at: http://www.salariuspharma.com
Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company’s lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
